Bamco Inc. NY purchased a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 315,789 shares of the conglomerate's stock, valued at approximately $227,381,000.
Several other hedge funds have also bought and sold shares of DHR. EP Wealth Advisors LLC purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $3,807,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Danaher by 303.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate's stock valued at $56,777,000 after buying an additional 186,584 shares during the last quarter. Puzo Michael J purchased a new position in shares of Danaher in the 2nd quarter valued at $8,624,000. Legal & General Group Plc raised its stake in Danaher by 1.0% during the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate's stock worth $1,029,061,000 after acquiring an additional 43,169 shares in the last quarter. Finally, Madison Asset Management LLC acquired a new stake in Danaher during the 2nd quarter worth $85,451,000. Hedge funds and other institutional investors own 79.05% of the company's stock.
Danaher Trading Down 0.0%
Shares of Danaher stock opened at $215.90 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a market capitalization of $151.77 billion, a P/E ratio of 38.35, a PEG ratio of 2.69 and a beta of 0.78. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company's fifty day moving average is $197.93 and its two-hundred day moving average is $192.36.
Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. During the same period in the prior year, the company earned $0.77 earnings per share. The business's revenue was up 5.5% compared to the same quarter last year. Analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.
Analyst Upgrades and Downgrades
DHR has been the subject of several research analyst reports. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, July 15th. Citigroup started coverage on Danaher in a report on Tuesday, May 26th. They issued a "buy" rating and a $230.00 target price for the company. Stifel Nicolaus decreased their target price on Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research report on Wednesday, July 22nd. Finally, HSBC dropped their price target on Danaher from $270.00 to $230.00 and set a "buy" rating on the stock in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.91.
Get Our Latest Research Report on Danaher
Danaher Profile
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
